CY1122426T1 - Παραγωγα 8-υδροξυ-κινολινης - Google Patents
Παραγωγα 8-υδροξυ-κινολινηςInfo
- Publication number
- CY1122426T1 CY1122426T1 CY20191101327T CY191101327T CY1122426T1 CY 1122426 T1 CY1122426 T1 CY 1122426T1 CY 20191101327 T CY20191101327 T CY 20191101327T CY 191101327 T CY191101327 T CY 191101327T CY 1122426 T1 CY1122426 T1 CY 1122426T1
- Authority
- CY
- Cyprus
- Prior art keywords
- group
- groups
- lower alkyl
- optionally substituted
- hydrogen atom
- Prior art date
Links
- 150000004325 8-hydroxyquinolines Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 230000036542 oxidative stress Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1000243A HUP1000243A2 (en) | 2010-05-06 | 2010-05-06 | 8-hidroxy-quinoline derivatives |
| PCT/HU2011/000043 WO2011148208A1 (en) | 2010-05-06 | 2011-05-06 | 8-hydroxy-quinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122426T1 true CY1122426T1 (el) | 2021-01-27 |
Family
ID=89989711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101327T CY1122426T1 (el) | 2010-05-06 | 2019-12-17 | Παραγωγα 8-υδροξυ-κινολινης |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8871937B2 (enExample) |
| EP (1) | EP2566849B1 (enExample) |
| JP (1) | JP5812541B2 (enExample) |
| KR (1) | KR101837974B1 (enExample) |
| CN (1) | CN102985407B (enExample) |
| AU (1) | AU2011256989B2 (enExample) |
| CA (1) | CA2798419C (enExample) |
| CY (1) | CY1122426T1 (enExample) |
| DK (1) | DK2566849T3 (enExample) |
| EA (1) | EA021026B1 (enExample) |
| ES (1) | ES2761832T3 (enExample) |
| HR (1) | HRP20192278T1 (enExample) |
| HU (2) | HUP1000243A2 (enExample) |
| MX (1) | MX337999B (enExample) |
| NZ (1) | NZ603967A (enExample) |
| PL (1) | PL2566849T3 (enExample) |
| PT (1) | PT2566849T (enExample) |
| RS (1) | RS59678B1 (enExample) |
| SI (1) | SI2566849T1 (enExample) |
| SM (1) | SMT201900710T1 (enExample) |
| WO (1) | WO2011148208A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP1500098A2 (hu) * | 2015-03-09 | 2016-09-28 | Avidin Kft | 8-hidroxikinolin származékok új enantiomerjei és szintézisük |
| WO2017066245A1 (en) * | 2015-10-12 | 2017-04-20 | Health Research, Inc. | Methods for inducing apoptosis in cancer cells |
| CN105367553A (zh) * | 2015-12-04 | 2016-03-02 | 广东工业大学 | 一种他克林-8-羟（胺）基喹啉衍生物及其应用 |
| HUP1600234A2 (en) | 2016-04-05 | 2017-12-28 | Mta Termeszettudomanyi Kutatokoezpont | Mdr-reversing 8-hydroxy-quinoline derivatives |
| WO2024073624A2 (en) * | 2022-09-28 | 2024-04-04 | The Research Foundation For The State University Of New York | Antiproliferative betti bases and prodrugs thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999015179A1 (en) | 1997-09-25 | 1999-04-01 | Regents Of The University Of Minnesota | Methods of limiting apoptosis of cells |
| US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
| AU2474399A (en) | 1998-01-26 | 1999-08-09 | Mitokor | Mitochondria protecting agents for treating mitochondria associated diseases |
| US6737511B1 (en) | 1999-08-16 | 2004-05-18 | The United States Of America As Represented By The Department Of Health And Human Services | Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis |
| DE60040397D1 (de) | 1999-08-27 | 2008-11-13 | Cytovia Inc | Substituierte alpha-hydroxy-säuren als caspase-hemmer und ihre verwendung |
| US6890896B1 (en) | 1999-11-18 | 2005-05-10 | Ceremedix, Inc. | Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
| US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
| US6534651B2 (en) | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
| GB0011095D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | astrin and cholecystokinin receptor ligands (III) |
| US6521617B2 (en) | 2000-10-13 | 2003-02-18 | The Johns Hopkins University | Treatment of apoptotic cell death |
| WO2002048092A2 (en) | 2000-12-15 | 2002-06-20 | Mitokor | Compounds for altering mitochondrial function and cellular responses |
| US7601846B2 (en) | 2001-06-26 | 2009-10-13 | The Regents Of The University Of California | Compounds having activity as inhibitors of apoptosis |
| EP1414948B1 (en) | 2001-07-10 | 2009-09-16 | Biogen Idec Inc. | Inhibition of apoptosis process and improvement of cell performance |
| DE10144153A1 (de) | 2001-09-07 | 2003-03-27 | Newfrey Llc | Halteclip mit versetzten Rastfingern |
| EA200401070A1 (ru) | 2002-02-13 | 2005-02-24 | Бет Изрейэл Диконисс Медикал Сентер, Инк. | Способы лечения сосудистых заболеваний |
| WO2005072295A2 (en) | 2004-01-23 | 2005-08-11 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| AU2004258801A1 (en) | 2003-02-28 | 2005-02-03 | Inotek Pharmaceuticals Corporation | Tetracyclic Benzamide Derivatives and methods of use thereof |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| ES2396334T3 (es) | 2003-05-28 | 2013-02-20 | Eisai Inc. | Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| US7462724B2 (en) | 2005-11-15 | 2008-12-09 | Abbott Laboratories | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors |
| US7528174B2 (en) | 2006-01-06 | 2009-05-05 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Selective targeting agents for mitochondria |
| CA2658793A1 (en) * | 2006-07-25 | 2008-02-07 | Daniel Dumas | Quinoline derivatives |
| EP2139460A4 (en) * | 2007-03-20 | 2011-09-07 | Univ Brandeis | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED NEUROLOGICAL DISEASES |
| US8183236B2 (en) * | 2007-04-12 | 2012-05-22 | University Of Southern California | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics |
| CA2687187A1 (en) | 2007-05-25 | 2008-12-18 | Burnham Institute For Medical Research | Inhibitors of thapsigargin-induced cell death |
| US8138356B2 (en) * | 2007-10-16 | 2012-03-20 | Angiogeney, Inc. | Chemical inhibitors of inhibitors of differentiation |
| US10301265B2 (en) * | 2008-05-28 | 2019-05-28 | Virginia I. Roxas-Duncan | Small molecule inhibitors of botulinum neurotoxins |
| EP2521551A4 (en) * | 2010-01-06 | 2013-08-21 | Errico Joseph P | METHOD AND COMPOSITIONS FOR TARGETED ACTIVE DEVELOPMENT |
| US8658170B2 (en) * | 2010-01-06 | 2014-02-25 | Joseph P. Errico | Combination therapy with MDM2 and EFGR inhibitors |
-
2010
- 2010-05-06 HU HU1000243A patent/HUP1000243A2/hu unknown
-
2011
- 2011-05-06 NZ NZ603967A patent/NZ603967A/en not_active IP Right Cessation
- 2011-05-06 DK DK11752335.7T patent/DK2566849T3/da active
- 2011-05-06 RS RS20191622A patent/RS59678B1/sr unknown
- 2011-05-06 AU AU2011256989A patent/AU2011256989B2/en not_active Ceased
- 2011-05-06 SM SM20190710T patent/SMT201900710T1/it unknown
- 2011-05-06 WO PCT/HU2011/000043 patent/WO2011148208A1/en not_active Ceased
- 2011-05-06 MX MX2012012883A patent/MX337999B/es active IP Right Grant
- 2011-05-06 EP EP11752335.7A patent/EP2566849B1/en active Active
- 2011-05-06 EA EA201270787A patent/EA021026B1/ru unknown
- 2011-05-06 HR HRP20192278TT patent/HRP20192278T1/hr unknown
- 2011-05-06 CA CA2798419A patent/CA2798419C/en active Active
- 2011-05-06 PL PL11752335T patent/PL2566849T3/pl unknown
- 2011-05-06 ES ES11752335T patent/ES2761832T3/es active Active
- 2011-05-06 CN CN201180033524.5A patent/CN102985407B/zh active Active
- 2011-05-06 KR KR1020127030702A patent/KR101837974B1/ko active Active
- 2011-05-06 JP JP2013508559A patent/JP5812541B2/ja active Active
- 2011-05-06 US US13/696,541 patent/US8871937B2/en active Active
- 2011-05-06 HU HUE11752335A patent/HUE050886T2/hu unknown
- 2011-05-06 SI SI201131826T patent/SI2566849T1/sl unknown
- 2011-05-06 PT PT117523357T patent/PT2566849T/pt unknown
-
2019
- 2019-12-17 CY CY20191101327T patent/CY1122426T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20192278T1 (hr) | 2020-03-06 |
| HU1000243D0 (en) | 2010-06-28 |
| CN102985407A (zh) | 2013-03-20 |
| US20130131096A1 (en) | 2013-05-23 |
| HUP1000243A2 (en) | 2012-01-30 |
| US8871937B2 (en) | 2014-10-28 |
| AU2011256989B2 (en) | 2014-08-21 |
| AU2011256989A1 (en) | 2013-01-10 |
| NZ603967A (en) | 2014-06-27 |
| JP5812541B2 (ja) | 2015-11-17 |
| SMT201900710T1 (it) | 2020-01-14 |
| DK2566849T3 (da) | 2020-01-02 |
| MX337999B (es) | 2016-03-30 |
| RS59678B1 (sr) | 2020-01-31 |
| EA201270787A1 (ru) | 2013-04-30 |
| HUE050886T2 (hu) | 2021-01-28 |
| CA2798419A1 (en) | 2011-12-01 |
| WO2011148208A1 (en) | 2011-12-01 |
| PT2566849T (pt) | 2020-01-06 |
| ES2761832T3 (es) | 2020-05-21 |
| KR20130029772A (ko) | 2013-03-25 |
| EA021026B1 (ru) | 2015-03-31 |
| PL2566849T3 (pl) | 2020-03-31 |
| KR101837974B1 (ko) | 2018-03-13 |
| SI2566849T1 (sl) | 2020-02-28 |
| EP2566849B1 (en) | 2019-09-18 |
| JP2013525473A (ja) | 2013-06-20 |
| CA2798419C (en) | 2021-01-05 |
| EP2566849A1 (en) | 2013-03-13 |
| MX2012012883A (es) | 2013-03-20 |
| CN102985407B (zh) | 2015-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122426T1 (el) | Παραγωγα 8-υδροξυ-κινολινης | |
| CY1116945T1 (el) | Παραγωγα ινδολιζινης, διεργασια για την παρασκευη αυτης και θεραπευτικη χρηση αυτης | |
| CY1117374T1 (el) | Παραγωγα ιμιδαζοπυριδινης, διαδικασια για την παρασκευη αυτων και θεραπευτικη χρηση αυτων | |
| CY1118390T1 (el) | Θεραπευτικος παραγων για τη φλεγμονωδη νοσο του εντερου | |
| CY1116405T1 (el) | Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης | |
| CY1121724T1 (el) | Ενωσεις για την αντιμετωπιση καρκινου | |
| HN2012001413A (es) | Derivados de pirazina y su uso en el tratamiento de trastornos neurólogicos | |
| CY1118739T1 (el) | Ενωσεις αμφι(φθoρoαλκυλ)-1,4-βενζoδιαζεπινoνης ως αναστολεις toy notch | |
| CY1125285T1 (el) | Θεραπεια για τη νοσο του παρκινσον | |
| NI201000107A (es) | Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa. | |
| CY1123533T1 (el) | Ν-αλκυλαρυλο-5-οξυαρυλο-οκταϋδρο-κυκλοπεντα [c] πυρρολια ως αρνητικοι αλλοστερικοι ρυθμιστες των nr2b | |
| CY1123670T1 (el) | Κρυσταλλικο παραγωγο 6,7-ακορεστης-7-καρβαμοϋλ μορφινανης, και μεθοδος για την παραγωγη αυτου | |
| CY1118610T1 (el) | Αναστολεις κινασεων και η χρηση τους στη θεραπευτικη αγωγη του καρκινου | |
| CO7141456A2 (es) | Derivados de aril-sultamo como moduladores de rorc | |
| CY1118102T1 (el) | Αλατα διαμινιου φαινοθειαζινης και η χρηση αυτων | |
| AR098912A1 (es) | Inhibidores de syk | |
| ECSP12011622A (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos | |
| UY33969A (es) | Inhibidores tricíclicos fusionados dobles de las cdk 4/6 y de la flt3 | |
| UY34451A (es) | Derivados de uracilo como inhibidores de la quinasa axl y c-met | |
| UY32096A (es) | Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones | |
| CY1119220T1 (el) | Μονοκυκλικο παραγωγο πυριδινης | |
| CY1117193T1 (el) | Φαρμακευτικη συνθεση για θεραπεια ή αποτροπη γλαυκωματος | |
| CY1119842T1 (el) | Συντηγμενες τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις ιντεγκρασης hiv | |
| CY1115800T1 (el) | Παραγωγα της 3-(ετεροαρυλο-αμινο)-1,2,3,4-τετραϋδρo-9η-καρβαζολης και η χρηση τους ως ρυθμιστες των υποδοχεων της προσταγλανδινης d2 | |
| CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas |